切换至 "中华医学电子期刊资源库"
高级检索
中华临床实验室管理电子杂志

中华临床实验室管理电子杂志 ›› 2019, Vol. 07 ›› Issue (04) : 234 -237. doi: 10.3877/cma.j.issn.2095-5820.2019.04.011

所属专题： 文献；

实验研究

髓过氧化物酶与脂蛋白相关磷脂酶A2在心血管疾病诊断中的应用
王英1,†(), 陈学军1   
  1. 1. 056001，邯郸市中医院检验科
  • 收稿日期:2019-08-13 出版日期:2019-11-28
  • 通信作者: 王英

Application of myeloperoxidase and lipoprotein associated phospholipase A2 in the diagnosis of cardiovascular diseases

Ying Wang1,†(), Xuejun Chen1   

  1. 1. Department of Clinical Laboratory, Handan Trantional Chinese Hospital, Handan 056001, China
  • Received:2019-08-13 Published:2019-11-28
  • Corresponding author: Ying Wang
  • About author:
    Corresponding author: Wang Ying, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

王英, 陈学军. 髓过氧化物酶与脂蛋白相关磷脂酶A2在心血管疾病诊断中的应用[J]. 中华临床实验室管理电子杂志, 2019, 07(04): 234-237.

Ying Wang, Xuejun Chen. Application of myeloperoxidase and lipoprotein associated phospholipase A2 in the diagnosis of cardiovascular diseases[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2019, 07(04): 234-237.

目的

比较心血管疾病患者与健康对照者血浆髓过氧化物酶(myeloperoxidase，MPO)和脂蛋白相关磷脂酶A2(lipoprotein-associated phospholipase A2，Lp-PLA2)水平的差异，评估MPO和Lp-PLA2在心血管疾病诊断中的作用。

方法

选取经冠状动脉造影和放射性核素标记等确诊的72例心血管疾病患者编为患病组，将68例健康体检者编为健康对照组。采用酶联免疫法检测两组受试者血浆中的MPO和Lp-PLA2水平，比较两组之间的差异，并对结果进行统计分析。

结果

通过比较患病组和健康对照组的MPO和Lp-PLA2水平，结果显示两组间有显著的统计学差异，患病的MPO和Lp-PLA2值明显高于健康对照组。ROC曲线显示MPO对心血管病的诊断准确度居于中等偏上，Lp-PLA2对心血管病的诊断准确度较高。

结论

心血管疾病患者血浆中的MPO和Lp-PLA2含量显著升高，提示MPO和Lp-PLA2对心血管病的具有诊断价值。

关键词: 髓过氧化物酶, 脂蛋白相关磷脂酶A2, 冠心病, 急性冠脉综合征, 酶联免疫
Objective

To compare plasma levels of myeloperoxidase (MPO) and lipoprotein-associated phospholipase A2 (Lp-PLA2) between patients with cardiovascular diseases and healthy controls, and to evaluate the role of MPO and Lp-PLA2 in the diagnosis of cardiovascular diseases.

Methods

Seventy-two patients with cardiovascular diseases confirmed by coronary angiography and radionuclide labeling were selected as the disease group, and 68 healthy people as the control group. The levels of plasma MPO and Lp-PLA2 of the two groups were measured by enzyme-linked immunosorbent assay (ELISA). The differences between the two groups were compared, and the results were statistical analyzed.

Results

By comparing the levels of MPO and Lp-PLA2 between the cardiovascular disease and the healthy control groups, the results showed that there was significant differences between the two gooups. The levels of MPO and Lp-PLA2 in the disease group were significantly higher than those in the healthy control group. ROC curve suggested that the diagnostic accuracy of MPO and Lp-PLA2 for cardiovascular diseases was higher than 50% and higher than 90%, respectively.

Conclusion

The levels of MPO and Lp-PLA2 in the plasma of patients with cardiovascular diseases significantly increases, suggesting their diagnostic value.

Key words: Myeloperoxidase, Lipoprotein-associated phospholipase A2, Coronary heart disease, Enzyme-linked immunosorbent assay
表1 患病组和健康对照组基本信息比较
组别 例数(例) 年龄(岁) 性别(男/女)
患病组 72 62.35±9.62 38/34
健康对照组 68 60.22±8.64 33/35
P值 ? 0.172 0.618
表2 患病和健康对照组MPO比较
组别 例数 MPO(ng/mL) Lp-PLA2(ng/mL) TC(mmol/L) LDL-C(mmol/L) HDL-C(mmol/L) TG(mmol/L)
患病组 72 123.78±32.03 230.28±45.42 4.82±0.93 3.53±0.81 1.14±0.26 1.76±0.76
健康对照组 68 74.97±29.74 147.60±37.36 4.67±0.65 3.34±0.47 1.11±0.13 1.70±0.43
t值 ? 9.711 11.726 1.373 1.136 1.578 0.862
P值 ? <0.05 <0.05 0.172 0.258 0.117 0.390
表3 Pearson相关性显著性(双侧)分析
? MPO Lp-PLA2 TC LDL-C HDL-C TG 年龄
MPO 1 0.782 0.053 0.026 0.044 0.021 0.007
? <0.05 0.535 0.757 0.609 0.807 0.933
Lp-PLA2 0.782 1 -0.009 0.027 0.034 -0.069 0.059
<0.05 ? 0.915 0.748 0.692 0.418 0.491
表4 MPO、Lp-PLA2预测分析
? 敏感度 特异性 总符合率 假阴性率 假阳性率 阳性预测值 阴性预测值
MPO 84.7% 76.5% 80.7% 15.3% 23.5% 79.2% 82.5%
Lp-PLA2 86.1% 83.8% 85.0% 13.9% 16.2% 84.9% 85.1%
图1 MPO和Lp-PLA2诊断冠心病的ROC曲线
1
Liu CG, Chen LN, Yang YZ, et al. Myeloperoxidase and high-sensitivity C-reactive protein for predicting major adverse cardiovascular events in patients with coronary heart disease[J]. Int J Clin Med, 2015,6:262-270.
2
Uydu HA, Bostan M, Yilmaz A, et al. Comparison of inflammatory biomarkersfor detection of coronary stenosis in patients with stable coronary artery disease[J]. Eur Rev Med Pharmacol Sci, 2013,17(1):112-118.
3
Khan AA, Alsahli MA, Rahmani AH. Myeloperoxidase as an active disease biomarker: recent biochemical and pathological perspectives[J]. Med Sci (Basel), 2018,6(2).pii: E33.
4
Wang J, Tan GJ, Han LN, et al. Novel biomarkers for cardiovascular risk prediction[J]. J Geriatr Cardiol, 2017,14(2):135-150.
5
胡大一，杨铁生，刘梅颜，等. 心脏分子标志物临床应用[M]. 北京：人民军医出版社, 2009:143-149.
6
许俊堂，丛玉隆. 抗栓与溶栓药物的血液学检测[J]. 中华检验医学杂志, 2001,24(1):53-55.
7
Roman RM, Camargo PV, Borges FK, et al. Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients[J]. Coron Artery Dis, 2010,21(3):129-136.
8
Mythili S, Malathi N. Diagnostic markers of acute myocardial infarction[J]. Biomed Rep, 2015,3(6):743-748.
9
Quidim AV, Bruno TC, Lacerda Leocádio PC, et al. Myeloperoxidase activity and acute coronary syndrome survival: long-term evaluation in the ERICO study[J]. Biomark Med, 2018,12(11):1219-1229.
10
Goiffon RJ, Martinez SC, Piwnica-Worms D. A rapid bioluminescence assay for measuring myeloperoxidase activity in human plasma[J]. Nat Commun, 2015,10(6):6271.
11
Kocak S, Ertekin B, Girisgin AS, et al. Lipoprotein-associated phospholipase-A2 activity and its diagnostic potential in patients with acute coronary syndrome and acute ischemic stroke[J]. Turk J Emerg Med, 2017,17(2):56-60.
12
Wright CB, Moon Y, Paik MC, et al. Inflammatory biomarkers of vascular risk as correlates of leukoaraiosis[J]. Stroke. 2009,40(11):3466-3471.
13
Yang L, Liu Y, Wang SF, et al. Association between Lp-PLA2 and coronary heart disease in Chinese patients[J]. J Int Med Res, 2017,45(1):159-169.
14
Rosenson RS, Stafforini DM. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2[J]. J Lipid Res, 2012,53(9):1767-1782.
15
Yang YP, Xue T, Zhu JH, et al. Serum lipoprotein-associated phospholipase A2 predicts the formation of carotid artery plaque and its vulnerability in anterior circulation cerebral infarction[J]. Clin Neurol Neurosurq, 2017,160:40-45.
16
Li JW, Wang H, Tian JP, et al. Change in lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndrome[J]. Medicine (Baltimore), 2018,97(28):e11517.
17
Omran MM, Zahran FM, Kadry M, et al. Role of myeloperoxidase in early diagnosis of acute myocardial infarction in patients admitted with chest pain[J]. J Immunoassay Immunochem, 2018,39(3):337-347.
18
Güngör ZB, Tüten A, Ekmekçi H, et al. Possible effects of lipoprotein-associated phospholipase A2 single-nucleotide polymorphisms on cardiovascular risk in patients with preeclampsia[J]. J Matern Fatal Med, 2018,31(23):3119-3127.
[1] 张婉微, 秦芸芸, 蔡绮哲, 林明明, 田润雨, 金姗, 吕秀章. 心肌收缩早期延长对非ST段抬高型急性冠脉综合征患者冠状动脉严重狭窄的预测价值[J]. 中华医学超声杂志（电子版）, 2023, 20(10): 1016-1022.
[2] 彭冠华, 张建琴, 钟龙和, 李莎莎, 唐颖, 刘俭, 吴爵非. 负荷超声心动图联合心肌声学造影评估缺血性心脏病患者临床预后的价值[J]. 中华医学超声杂志（电子版）, 2022, 19(12): 1342-1348.
[3] 葛飞霞, 蒋银, 杨丹. 酶联免疫吸附测定法与PCR仪检测在乙型肝炎诊断中的临床应用[J]. 中华危重症医学杂志(电子版), 2023, 16(04): 310-315.
[4] 沈杨, 余海波, 曾强英. 外周血可溶性Fas蛋白及其配体、髓过氧化物酶水平对重症肺炎患儿预后不良的预测价值[J]. 中华实验和临床感染病杂志(电子版), 2022, 16(04): 268-274.
[5] 林蕊艳, 张新, 杨晶晶, 周建群. 痰热清注射液联合正压通气治疗睡眠呼吸暂停低通气综合征的临床分析[J]. 中华肺部疾病杂志(电子版), 2022, 15(04): 530-532.
[6] 阿依别克·吐尔得汉, 陈伦牮, 巴合体·卡力甫, 陈雄, 梦塬. 血清免疫抗原在包虫病诊断中的价值Meta分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(03): 300-304.
[7] 陈捷, 周峰, 刘金波, 王宏宇. 基于聚类的冠心病患者药物治疗模式及人群异质性研究[J]. 中华临床医师杂志(电子版), 2022, 16(10): 1012-1018.
[8] 唐红燕, 丹海俊, 高志红, 张作阳, 翟书梅, 吴少玉, 张玉. 心脏彩色多普勒超声在冠心病慢性心力衰竭患者临床诊断中的应用[J]. 中华临床医师杂志(电子版), 2022, 16(07): 676-679.
[9] 蔡琦, 雍永宏, 何花, 佘铜生, 俞慧. 三维斑点追踪技术联合血清同型半胱氨酸对冠心病患者左心功能的评估价值[J]. 中华临床医师杂志(电子版), 2022, 16(05): 425-430.
[10] 樊茹, 刘红伟, 邱万, 李晓非. I-SPOT.TB与T-SPOT.TB试剂盒在结核病诊断中的应用价值及其诊断一致性分析[J]. 中华临床实验室管理电子杂志, 2022, 10(04): 210-214.
[11] 郭义城, 谢志鹏, 刘万里, 赵阳, 车艳生, 赵敏. 胸12椎体骨质疏松性椎体压缩骨折致心前区牵涉痛误诊为冠心病特征分析[J]. 中华诊断学电子杂志, 2023, 11(02): 136-139.
[12] 黄大军, 李燕伟, 伍洲, 张嬿, 康彧, 孔令秋. Takotsubo综合征心电图的进展[J]. 中华心脏与心律电子杂志, 2023, 11(02): 120-123.
[13] 郭少华, 耿世佳, 洪申达, 穆冠宇, 张一芝, 杨磊, 刘彤, 陈康寅. 人工智能辅助心电图识别无冠心病人群的临床研究[J]. 中华心脏与心律电子杂志, 2023, 11(01): 18-23.
[14] 张海凤, 周梦竹, 霍宁, 陈砚戈, 富华颖, 刘彤, 李广平, 刘长乐. 漂浮导管监测下的介入治疗在高危重症冠心病患者中的应用[J]. 中华心脏与心律电子杂志, 2022, 10(04): 209-214.
[15] 孙格, 杨艳敏. 心房颤动合并急性冠脉综合征或经皮冠状动脉介入术后三联抗栓治疗的降阶策略[J]. 中华心脏与心律电子杂志, 2022, 10(04): 204-208.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号